It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Previous reports have shown that during chronic inflammation, the tryptophan (TRP)-kynurenine (KYN) pathway plays a pivotal role in the onset of depression. The aim of this study was to investigate the characteristics of the serum TRP-KYN pathway metabolite profile in high-risk subjects of major depressive disorder (HRMDD) defined by depression scores. The concentrations of TRP-KYN pathway metabolites {TRP, KYN, 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), kynurenic acid (KYNA) and anthranilic acid (AA)} were assessed in serum from HRMDD, chronic pain disorder patients and healthy controls. In serum from HRMDD, elevated levels of AA and decreased levels of TRP were observed, but the levels of other metabolites were not changed. Furthermore, the change in the AA2nd/AA1st ratio in subjects who progressed from a healthy state to a depressive state was correlated with an increase in the CES-D score. The level of IL-1 receptor antagonist (IL-1RA) was negatively correlated with that of AA. Interestingly, we confirmed AA as a possible biomarker for depression-related symptoms, since the metabolite profiles in the chronic pain disorder group and chronic unpredictable mild stress model mice were similar to those in the HRMDD. These results suggest that AA may be an effective marker for HRMDD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
2 Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033); Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X)
3 Fujita Health University Graduate School of Health Sciences, Department of Regulatory Science, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X)
4 Fujita Health University Graduate School of Health Sciences, Department of Regulatory Science, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X); Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.256115.4)
5 Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X)
6 Matsunami Research Park, Gifu, Japan (GRID:grid.256115.4)
7 Nagoya University, Graduate School of Medicine, Department of Psychiatry, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
8 Aichi Gakuin University, Department of Oral and Maxillofacial, Surgery, School of Dentistry, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594)
9 Aichi Gakuin, University, Department of Anesthesiology, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594)
10 Nagoya University, Graduate School of Medicine, Department of Psychopathology and Psychotherapy/Center for Student Counseling, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
11 Aichi Gakuin University, Faculty of Psychological and Physical Sciences, Health Service Center, Nisshin, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594)
12 Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.27476.30); Fujita Health University Graduate School of Health Sciences, Advanced Diagnostic System Research Laboratory, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X)
13 Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033); Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X); Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.256115.4)